Nicotine replacement therapy â€¦ - Carlos A ... - Entretiens du Carla

More documents

Recommendations

Info

. Summary Summary - Summary - Summary - Summary Participants ------------------------- p. 3 Thanks E. André ------------------------------ p. 4 Chairmen Introduction J.A. Costa e Silva ---------------------- p. 4 Conclusions Synthesis with the contributions of ------ p. 6 P. Bartsch, G. Lagrue, S. Nardini, J. Perriot Introduction--------------------------- p. 6 Regulatory status by country-------------- p. 8 Increase in the prescribed dose and possibility to combine 2 NRTs ---------------------- p. 8 NRT for Temporary Abstinence (TA) -------- p. 9 The proper use of NRT to reduce tobacco consumption -------------------------- p. 10 Specific indications, limitations and Contraindications----------------------- p. 12 The case of snus------------------------ p. 13 Conclusions en français Synthèse avec les contributions de ------- p. 14 P. Bartsch, G. Lagrue, S. Nardini, J. Perriot Introduction--------------------------- p. 14 Situation réglementaire par pays ---------- p. 16 Augmentation de la dose prescrite et possibilité d’associer 2 TSN ------------------------ p. 16 Les TSN en abstinence temporaire (AT) ------ p. 17 Le bon usage des TSN dans la réduction de la consommation de tabac --------- ------- .18 Indications spécifiques, limites et contre-indications -----------------------p 20 Le cas du snus --------------------------p. 21 Session 1 Current situation of Indications and Contraindications for Nicotine Replacement Therapies Synthesis with the contribution of représentatives from EU countries Participants and E. Kralikova (CZ) ----------- p. 23 Session 2 NRTs in subjects under the age of 18 in case of pregnancy or cardiovascular diseases Use of NRTs among adolescents J.P. Zellweger -------------------------- p. 32 Recommendations during pregnancy T. Coleman ---------------------------- p. 36 Cardiovascular safety of NRTs D. Thomas ---------------------------- p. 42 Session 3 Reduction in consumption Reducing cigarette’s consumption J. Perriot------------------------------- p. 48 Session 4 Increase in the prescribed dose and possibility to combine 2 NRTs How to optimise the effectiveness of nicotine replacement therapies? I. Berlin ------------------------------- p. 58 Session 5 Temporary cessation Nicotine replacement therapy for temporary abstinence C. Jiménez-Ruiz ------------------------ p. 64 Session 6 European Program PESCE J. Daver ------------------------------ p. 72 2
Participants - Participants Participants - Participants - Participants Pierre BARTSCH Pneumology Belgium Ivan BERLIN Pharmacology France Hedwig BOUDREZ Psychology Belgium Magdalena CIOBANU Pneumology Roumania Tim COLEMAN Physician England Jorge-Alberto COSTA e SILVA Psychiatry Brazil Jean DAVER Biology France Mervi HARA Public Health Finland Giovanni INVERNIZZI Pneumology Italy Carlos JIMENEZ-RUIZ Pneumology Spain George KOTAROV Public Health Bulgaria Stefano NARDINI Pneumology Italy Paraskevi PATAKA Pneumology Greece Jean PERRIOT Pneumology France Robert RUSU Pneumology Luxembourg Rudolph SCHOBERBERGER Psychology Austria Daniel THOMAS Cardiology France Imre VADASZ Public Health Hungary Fleur VAN BLADEREN Public Health The Netherlands Paulo VITORIA Psychology Portugal Jean-Pierre ZELLWEGER Pneumology Switzerland By E-mail Eva KRALIKOVA Public Health Czech Republic Pierre Fabre participants Étienne ANDRÉ Public health Jacques CHEVALLET Pierre Fabre Santé Manager Philippe CROUZIT Pharmacist, France Marketing Manager Clément LAUR IDPF, Development Project Manager Jean-Marie PIBOURDIN Pierre Fabre Santé, Medical Director Guillaume RANDAXHE Project Manager OTC Nabil SAICHI IDPF, Clinical trials 3 Participants
Page 1: Nicotine Replacement Therapies Cons
Page 5 and 6: Participants - Participants Partici
Page 7 and 8: Conclusion 1 Nicotine Replacement T
Page 9 and 10: NRT for Temporary Abstinence (TA) C
Page 11 and 12: Conclusion 7 Oral form or Patches f
Page 13 and 14: The case of snus Conclusion 13 A ha
Page 15 and 16: Conclusion 1 Traitement de substitu
Page 17 and 18: Les TSN en abstinence temporaire (A
Page 19 and 20: Conclusion 7 Formes orales ou patch
Page 21: Le cas du Snus Conclusion 13 Une su
Page 24 and 25: COUNTRY NRT available AUSTRIA BELGI
Page 26 and 27: COUNTRY NRT available FRANCE GERMAN
Page 28 and 29: COUNTRY NRT available MALTA POLAND
Page 31 and 32: Session 2 NRTs in subjects under th
Page 33 and 34: Figure 2. Flowchart depicting the a
Page 35 and 36: Discussion Smoking is a serious pro
Page 37 and 38: Effective treatments for Smoking Ce
Page 39 and 40: ate and lesser, concomitant effects
Page 41 and 42: Recommendations for clinical practi
Page 43 and 44: explain why it increases chemorefle
Page 45: Table 2. In practice Based on all t
Page 48 and 49: Reducing cigarettes consumption Jea
Page 50 and 51: Figure 2 - Point Prevalence Reducti
Page 52 and 53:
• Other studies have demonstrated
Page 54 and 55:
P. Crouzit. motivation to quit is l
Page 57 and 58:
Session 4 Increase in the prescribe
Page 59 and 60:
Use of high-dose NRT As a rule, inc
Page 61:
Tailored dose adjustment of NRT A s
Page 64 and 65:
References (1) Hughes J, Callas P,
Page 66 and 67:
(15) Fiore MC, Jaen CR et al. Treat
Page 68 and 69:
(27) Broms U et al. Smoking reducti
Page 71 and 72:
Session 6 European Program PESCE 71
Page 73 and 74:
1. To what extent do GPs in Europe
Page 75 and 76:
7. Simple recording systems on smok
show all

Nicotine replacement therapy â€¦ - Carlos A ... - Entretiens du Carla

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?